ConductScience.org, home

Paper29909019

Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.

Rutgeerts P and 12 others. Gastroenterology, 2018. Cited by 155 papers, by iCite.

Cite this record

ConductScience Library. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. Papers, record 29909019. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29909019

Download JSON
Disease
Crohn disease198 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
PubMed
Journal
Gastroenterology
PubMed
Year
2018
PubMed
Publication types
Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
155
iCite
Relative citation ratio, by iCite
6.45
iCite
Revised in PubMed
2022-04-10
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rutgeerts PPaul
2Gasink CChristopher
3Chan DDaphne
4Lang YYinghua
5Pollack PPaul
6Colombel JFJean-Frederic
7Wolf DCDouglas C
8Jacobstein DDouglas
9Johanns JJewel
10Szapary PPhilippe
11Adedokun OJOmoniyi J
12Feagan BGBrian G
13Sandborn WJWilliam J

Source PubMed

Download CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Inflammatory AgentsMajor topic
ColonMajor topic
ColonoscopyMajor topic
Crohn DiseaseMajor topic
Gastrointestinal AgentsMajor topic
UstekinumabMajor topic
Wound HealingMajor topic
Administration, Intravenous
Adult
Female
Humans
Induction Chemotherapy
Maintenance Chemotherapy
Male
Middle Aged
Predictive Value of Tests
Prospective Studies
Remission Induction
Severity of Illness Index
Time Factors
Treatment Outcome

Source PubMed

Download CSV of topics

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01369329
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Derived from the trialYesClinicalTrials.gov
NCT01369342A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)Derived from the trialYesClinicalTrials.gov
NCT01369355A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)Derived from the trialYesClinicalTrials.gov

Download CSV of trials

Cited by90

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 155 citations.

PMIDTitleJournalYearIn PapersSource
42899159The aryl hydrocarbon receptor and kynurenine pathway: connecting inflammatory bowel disease and depression via the microbiota gut brain axis.Front Neurosci2026https://conductscience.org/library/papers/42899159PubMed
42609442Inflammatory Bowel Disease: Mechanisms and Therapeutic Advances.MedComm (2020)2026https://conductscience.org/library/papers/42609442PubMed
42205859A decade of clinical data with vedolizumab: the past, present, and future.Ther Adv Gastroenterol2026https://conductscience.org/library/papers/42205859PubMed
42195154A Comparative Study of Different Biological Drugs in First-Line Therapy in Crohn's Disease: A Multicenter Descriptive Analysis.Medicina (Kaunas)2026https://conductscience.org/library/papers/42195154PubMed
41930211Analysis of the use of monoclonal antibodies in the treatment of Crohn's disease.Antib Ther2026https://conductscience.org/library/papers/41930211PubMed
41852927Once-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn's disease (PIZZICATO): an international, randomised, phase 2a trial.EClinicalMedicine2026https://conductscience.org/library/papers/41852927PubMed
41843763Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg.J Crohns Colitis2026https://conductscience.org/library/papers/41843763PubMed
41553714Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis.Adv Ther2026https://conductscience.org/library/papers/41553714PubMed
41458359Development of Predictive Models for Long-Term Endoscopic Response to Ustekinumab in Crohn's Disease Based on Plasma Proteomics.J Inflamm Res2025https://conductscience.org/library/papers/41458359PubMed
41339249Efficacy and safety of IL-23p19 and IL-12/23p40 inhibitors in moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.Ann Med2025https://conductscience.org/library/papers/41339249PubMed
41002400Predictive Role of MicroRNAs in the Diagnosis and Management of Patients with Crohn's Disease: A Clinician's View.Cells2025https://conductscience.org/library/papers/41002400PubMed
40722847Insights into the Molecular Mechanisms and Novel Therapeutic Strategies of Stenosis Fibrosis in Crohn's Disease.Biomedicines2025https://conductscience.org/library/papers/40722847PubMed
40708467Imbalance between skeletal muscle and intermuscular fat predicts treatment failure in Crohn's disease: an imaging biomarker for risk stratification.Ann Med2025https://conductscience.org/library/papers/40708467PubMed
40693590Effectiveness, treatment pattern, and safety of ustekinumab in treating bio-naïve patients with Crohn's disease in the real-world clinical setting in China.Chin Med J (Engl)2026https://conductscience.org/library/papers/40693590PubMed
40417421Short-Term Effectiveness of Ustekinumab in Crohn's Disease: Results from a Real-World Retrospective Multicenter Study in China.Int J Gen Med2025https://conductscience.org/library/papers/40417421PubMed
40323342Differentiating IL-23 Inhibitors in Crohn's Disease.Drugs2025https://conductscience.org/library/papers/40323342PubMed
40243170Pancreatic Enzyme Replacement Therapy Improves Exclusive Enteral Nutrition Related Diarrhea in Crohn's Disease: A Prospective Randomized Trial.United European Gastroenterol J2025https://conductscience.org/library/papers/40243170PubMed
40186719Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems.Clin Exp Med2025https://conductscience.org/library/papers/40186719PubMed
40142602Relapse Rates and Predictors for Relapse in Ulcerative Colitis and Crohn's Disease Patients After Discontinuation of Vedolizumab or Ustekinumab: The REVEUS Study.J Clin Med2025https://conductscience.org/library/papers/40142602PubMed
39990514What is first-line and what is second-line therapy in adult patients with moderate to severe Crohn's disease?J Can Assoc Gastroenterol2025https://conductscience.org/library/papers/39990514PubMed

See all 90 cited byDownload CSV of cited by

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
USTEKINUMABCHEMBL1201835Derived from the trial3https://conductscience.org/library/drugs/CHEMBL1201835

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29909019

GET https://conductscience.org/api/papers/v1/29909019/cited_by?page=2